Accendra Health Inc/va/ (ACH) · Oct 9, 2026 · Delisting
NYSE price deficiency — Average closing price below $1.00 for 30 consecutive trading days
Accendra Health disclosed an NYSE listing deficiency after shares averaged below $1, opening a six-month cure window and possible reverse split.
Accendra Health is a newly focused home-based-care company built around its Apria and Byram brands after exiting its former Products & Healthcare Services business; its strategy is to invest in technology, automation, and a simpler operating model for care delivered at home.
The filing creates a real listing-compliance problem, not an operational shutdown. The NYSE notified Accendra that its average closing price was below $1.00 for 30 consecutive trading days. The stock remains listed for now, but the notice confirms that the market-value pressure has crossed a formal exchange threshold.
The immediate business impact is limited, but the capital-markets signal is materially worse. The company has six months from the October 6 notice to regain compliance and must tell the NYSE within 10 business days that it intends to cure the deficiency. 〔0〕 That makes this partly known rather than wholly new: the low share price was visible beforehand, but the formal notice and cure clock are new disclosures.
A reverse split is now an explicit potential next step. Accendra says it is considering several alternatives, including a reverse stock split requiring shareholder approval no later than its anticipated May 2027 annual meeting. 〔1〕 That would address the quoted share-price requirement mechanically, not solve the underlying weakness that caused the shares to remain below $1.00; that distinction is the central negative takeaway.
The filing does not change the home-care operation itself today. The company says the notice has no immediate effect on its listing, business, operations, or SEC reporting obligations. 〔2〕 But compared with the standing assumption that the newly focused Apria/Byram platform could execute without a listing overhang, this adds a meaningful financing, shareholder-approval, and credibility complication.
Bottom line: This is a significant negative development for the company’s public-market standing, though not an immediate delisting or operating disruption. Accendra now has six months to restore the share-price requirement, with a reverse split increasingly part of the contingency plan.
NYSE cure response, due within 10 business days
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!